StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Equities researchers at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Eagle Pharmaceuticals stock opened at $5.74 on Wednesday. Eagle Pharmaceuticals has a 1 year low of $3.21 and a 1 year high of $23.52. The firm has a 50 day moving average price of $4.69 and a 200 day moving average price of $5.01. The company has a market cap of $74.56 million, a price-to-earnings ratio of 4.86 and a beta of 0.51.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Eagle Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after buying an additional 2,630 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in Eagle Pharmaceuticals by 110.1% during the first quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after buying an additional 100,470 shares in the last quarter. Trexquant Investment LP lifted its position in Eagle Pharmaceuticals by 88.0% during the fourth quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock valued at $660,000 after buying an additional 59,095 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Eagle Pharmaceuticals by 378.7% during the fourth quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock valued at $464,000 after buying an additional 70,158 shares in the last quarter. Finally, DGS Capital Management LLC lifted its position in Eagle Pharmaceuticals by 442.5% during the first quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock valued at $325,000 after buying an additional 50,525 shares in the last quarter. 85.36% of the stock is owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.